Intercept raises $30m for first-in-class liver candidate
This article was originally published in Scrip
Executive Summary
Intercept Pharmaceuticals has raised $30 million in a series C financing which will help it progress its lead candidate OCA (obeticholic acid), a first-in-class farnesoid X receptor (FXR) agonist in Phase III development for primary biliary cirrhosis (PBC).